June 19, 2019 | English | عربي
Add to Twitter
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
• CAROLINA® demonstrated no increased cardiovascular risk for Trajenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor

• Adults with diabetes treated with Trajenta® experienced significantly fewer events of hypoglycaemia and a modest weight reduction compared to patients treated with glimepiride

• Detailed results from CAROLINA® were presented at the American Diabetes Association’s 79th Scientific Sessions